Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration by Leung, Samuel C Y et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analytical validation of a standardised scoring protocol for Ki67
immunohistochemistry on breast cancer excision whole
sections: an international multicentre collaboration
Citation for published version:
Leung, SCY, Nielsen, TO, Zabaglo, LA, Arun, I, Badve, SS, Bane, AL, Bartlett, JMS, Borgquist, S, Chang,
MC, Dodson, A, Ehinger, A, Fineberg, S, Focke, CM, Gao, D, Gown, AM, Gutierrez, C, Hugh, JC, Kos, Z,
Lænkholm, A, Mastropasqua, MG, Moriya, T, Nofechmozes, S, Osborne, CK, Penaultllorca, FM, Piper, T,
Sakatani, T, Salgado, R, Starczynski, J, Sugie, T, Vegt, B, Viale, G, Hayes, DF, Mcshane, LM & Dowsett, M
2019, 'Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast
cancer excision whole sections: an international multicentre collaboration', Histopathology.
https://doi.org/10.1111/his.13880
Digital Object Identifier (DOI):
10.1111/his.13880
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Histopathology
Publisher Rights Statement:
This is a pre-copyedited, author-produced version of an article accepted for publication in Histopathology
following peer review. The version of record "Analytical validation of a standardised scoring protocol for Ki67
immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration"  is
available online at:https://doi.org/10.1111/his.13880
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. May. 2020
1 
 
1 
 
Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on 1 
breast cancer excision whole sections: an international multicentre collaboration 2 
 3 
S C Y Leung,1 T O Nielsen,1 L A Zabaglo,2 I Arun,3 S S Badve,4 A L Bane,5 J M S  Bartlett,6,22 S 4 
Borgquist,7 M C Chang,8 A Dodson,9 A Ehinger,10 S Fineberg,11 C M Focke,12 D Gao,1 A M 5 
Gown,13 C Gutierrez,14 J C Hugh,15 Z Kos,16 A-V Lænkholm,17 M G Mastropasqua,18 T Moriya,19 6 
S Nofech-Mozes,20 C K Osborne,14 F M Penault-Llorca,21 T Piper,22 T Sakatani,23 R Salgado,24,25 7 
J Starczynski,26 T Sugie,27 B van der Vegt,28 G Viale,18,29 D F Hayes,30 L M McShane31 & M 8 
Dowsett2 on behalf of the International Ki67 in Breast Cancer Working Group of the Breast 9 
International Group and North American Breast Cancer Group (BIG–NABCG). 10 
 11 
1University of British Columbia, Vancouver, British Columbia, Canada, 2The Institute of Cancer 12 
Research, London, UK, 3Tata Medical Center, Kolkata, West Bengal, India, 4Indiana University 13 
Simon Cancer Center, Indianapolis, Indiana, USA, 5Juravinski Hospital and Cancer Centre, 14 
McMaster University, Hamilton, Ontario, Canada, 6Ontario Institute for Cancer Research, 15 
Toronto, Ontario, Canada, 7Division of Oncology and Pathology, Department of Clinical Science, 16 
Lund University, Lund, Sweden, 8Department of Pathology and Laboratory Medicine, University 17 
of Vermont Medical Center, Burlington, VT, USA, 9Ralph Lauren Centre for Breast Cancer 18 
Research, The Royal Marsden Hospital, London, UK, 10Department of Clinical Genetics and 19 
Pathology, Skane University Hospital, Lund University, Lund, Sweden, 11Montefiore Medical 20 
Center and the Albert Einstein College of Medicine, Bronx, NY, USA, 12Dietrich-Bonhoeffer 21 
Medical Center, Neubrandenburg, Mecklenburg-Vorpommern, Germany, 13PhenoPath 22 
Laboratories, Seattle, Washington, DC, USA, 14Lester and Sue Smith Breast Center and Dan L. 23 
2 
 
2 
 
Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA, 24 
15University of Alberta, Edmonton, Alberta, Canada, 16University of Ottawa and The Ottawa 25 
Hospital, Ottawa, Ontario, Canada, 17Department of Surgical Pathology, Zealand University 26 
Hospital, Slagelse, Region Sjælland, Denmark, 18European Institute of Oncology, Milan, Italy, 27 
19Kawasaki Medical School, Kurashiki, Okayama Prefecture, Japan, 20University of Toronto 28 
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada, 21Centre Jean Perrin and 29 
Université d’Auvergne, Clermont-Ferrand, France, 22Edinburgh Cancer Research Centre, 30 
Western General Hospital, Edinburgh, UK, 23Nippon Medical School, Bunkyo-ku, Tokyo, Japan, 31 
24Department of Pathology, GZA-ZNA, Antwerp, Belgium, 25Division of Research, Peter 32 
MacCallum Cancer Centre, Melbourne, Australia, 26Birmingham Heart of England, National 33 
Health Service, Birmingham, UK, 27Kansai Medical University, Hirakata, Osaka, Japan, 34 
28University Medical Center Groningen, Groningen, the Netherlands, 29University of Milan, 35 
Milan, Italy, 30University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA, and 31National 36 
Cancer Institute, Bethesda, MD, USA 37 
 38 
Short title: Standardised visual scoring of Ki67 in breast cancer 39 
Keywords: Ki67, immunohistochemistry, pathology, scoring protocol, analytical validity, 40 
interobserver variability, interobserver reproducibility 41 
Address for correspondence: Samuel Leung, Room 509, 2660 Oak Street, Jack Bell Research 42 
Center, Vancouver, BC, V6H 3Z6, Canada. e-mail: sam.leung@vch.ca 43 
 44 
Aims: The nuclear proliferation marker Ki67 assayed by immunohistochemistry has multiple 45 
potential uses in breast cancer, but an unacceptable level of interlaboratory variability has 46 
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hampered its clinical utility. The International Ki67 in Breast Cancer Working Group has 47 
undertaken a systematic programme to determine whether Ki67 measurement can be analytically 48 
validated and standardised among laboratories. This study addresses whether acceptable scoring 49 
reproducibility can be achieved on excision whole sections. 50 
Methods and results: Adjacent sections from 30 primary ER+ breast cancers were centrally stained 51 
for Ki67 and sections were circulated among 23 pathologists in 12 countries. All pathologists 52 
scored Ki67 by two methods: (a) global: four fields of 100 tumour cells each were selected to 53 
reflect observed heterogeneity in nuclear staining; (b) hot-spot: the field with highest apparent 54 
Ki67 index was selected and up to 500 cells scored. The intraclass correlation coefficient (ICC) 55 
for the global method [confidence interval (CI) = 0.87; 95% CI = 0.799–0.93] marginally met the 56 
prespecified success criterion (lower 95% CI ≥ 0.8), while the ICC for the hot-spot method (0.83; 57 
95% CI = 0.74–0.90) did not. Visually, interobserver concordance in location of selected hot-spots 58 
varies between cases. The median times for scoring were 9 and 6 min for global and hot-spot 59 
methods, respectively. 60 
Conclusions: The global scoring method demonstrates adequate reproducibility to warrant next 61 
steps towards evaluation for technical and clinical validity in appropriate cohorts of cases. The 62 
time taken for scoring by either method is practical using counting software we are making 63 
publicly available. Establishment of external quality assessment schemes is likely to improve the 64 
reproducibility between laboratories further.  65 
 66 
Introduction 67 
The nuclear antigen recognised by the Ki67 antibody is expressed in proliferating cells but absent 68 
in resting cells.1 Since its discovery in 1983 by Gerdes et al.,1 Ki67 assessed by immunostaining 69 
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has been studied extensively as a prognostic2–11 and predictive4,6,9,12,13 marker, predominantly in 70 
hormone receptor-positive breast cancer, but also in other tumours.14–18 For example, presurgical 71 
Ki67 has been shown to be a marker for recurrence-free survival19 and, in the neoadjuvant setting, 72 
a marker for endocrine-resistant tumour that may require more aggressive treatment.20 Excellent 73 
intra-observer reproducibility under controlled pre-analytical and staining conditions21 has 74 
contributed to the body of evidence showing the potential of Ki67 immunohistochemistry assay to 75 
be implemented in hospital laboratories as a cost-effective part of clinical management.22–24 76 
However, poor interobserver reproducibility and variability due to technical aspects of the assay 77 
has limited its adoption in clinical practice.4,9,25–28 78 
The International Ki67 Working Group (IKWG) has undertaken a systematic multiphase 79 
programme to determine whether Ki67 scoring can be standardised and analytically validated 80 
throughout laboratories.9,21,29,30 In Phase I, as assessed by the intraclass correlation coefficient 81 
(ICC) estimate of interobserver reproducibility, differences in pathologists’ visual interpretation 82 
were the main source of variability (ICC = 0.71, 95% credible interval (CI) = 0.47–0.78).21 Greater 83 
concordance was achieved in Phase II, at least on tissue microarrays, when pathologists were 84 
trained to calibrate and standardise scoring according to a clearly defined methodology 85 
(ICC = 0.94, 95% CI = 0.90–0.97).29 However, in clinical practice, decisions are made on core-cut 86 
biopsy or excision specimens, which require general assessment of the entire sample and selection 87 
of areas for formal counting. Therefore, in Phase IIIA, we assessed whether acceptable 88 
performance could be achieved on core-cut biopsies using a standardised method with two distinct 89 
methods of scoring field selection: global (four representative fields, counting 100 nuclei each) 90 
and hot-spot (one field with highest Ki67, counting 500 nuclei). The global method achieved 91 
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acceptable interobserver reproducibility (ICC = 0.87; 95% CI = 0.81–0.93) according to our 92 
prespecified criteria, whereas the hot-spot method did not (ICC = 0.84; CI = 0.77–0.92).30 93 
The current study represents the final Phase (IIIB) of the visual scoring analytical validity 94 
programme, wherein we assess whether acceptable performance can be achieved on centrally 95 
stained excision whole sections using the scoring method established on core-cut biopsies. Future 96 
studies will be required to evaluate variability due to staining and pre-analytical aspects of the 97 
assay.  98 
 99 
Materials and methods 100 
This study was approved by the British Columbia Cancer Agency Clinical Research Ethics Board 101 
(H10-03420). All specimens used in this study were donated by patients who signed institutionally 102 
appropriate consent forms, were excess to diagnostic requirements, and ethically available for 103 
quality control studies.  104 
 105 
CASE SELECTION AND SAMPLE PREPARATION 106 
Excision blocks from 30 oestrogen receptor (ER)-positive breast cancer cases were selected: 15 107 
from the Phase IIIA study30 and 15 from Kawasaki Medical School Hospital, Kurashiki, Japan 108 
(Supporting information, Figure S1). Case selection was irrespective of patients’ age at diagnosis, 109 
tumour grade, size or nodal status. The clinicopathological characteristics of these 30 cases are 110 
shown in Supporting information, Table S1. All blocks were sectioned and stained in the Royal 111 
Marsden Hospital Histopathology Department using monoclonal antibody MIB1 at dilution 1:50 112 
(Dako UK, Ely, UK) using an automated staining system (Ventana Medical Systems, Tucson, AZ, 113 
USA) according to criteria established by the IKWG.9 Sections from the same block were stained 114 
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in a single immunohistochemistry run, except for four cases where the staining was performed in 115 
two different runs. This approach effectively controls for any technical variation in staining.  116 
 117 
SAMPLE DISTRIBUTION 118 
Twenty-four volunteer pathologists representing 24 institutions from 12 countries, most of whom 119 
participated in the Phase IIIA study, were invited to participate. 120 
Six adjacent sections from each of the 30 excision blocks were centrally stained: the first 121 
with haematoxylin and eosin (H&E), the second with p63 (myoepithelial marker, to assist the 122 
identification of invasive foci) and the third to sixth with Ki67 (designated as slide sets 1–4). To 123 
facilitate application to the general histopathology laboratory environment, physical glass slides 124 
(as opposed to virtual slide images) were distributed to the volunteer pathologists. Because the 125 
accumulated delays required would have made the study impractical if all pathologists reviewed 126 
the same physical glass slides, participating pathologists were divided into four groups and were 127 
given one of the four sets of Ki67 slides to score. The H&E and p63 reference slides were made 128 
available online as digital images. Twenty-three pathologists successfully completed the study. 129 
 130 
SCORING PROTOCOL 131 
All pathologists were specifically trained to score Ki67 with emphasis on having a very low 132 
threshold for appreciating ‘brown stain’ and the principles of standardised regions for nuclei 133 
counting, through the publicly available proficiency training module 134 
(http://www.gpec.ubc.ca/calibrator) that was initially used in the Phase II study.29 The detailed 135 
scoring protocol is found in the Supporting information document: 136 
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‘ki67p3b_scoring_protocol.pdf’. A modified version of the scoring software used in this study is 137 
available freely from the Google Play and Apple iTunes store (search term: ‘Ki67’). 138 
 139 
SCORING METHODS 140 
The scoring methods used were the same as those employed in the Phase IIIA study:30 (1) a global 141 
assessment that is weighted according to the estimated percentage of the total cancer area covered 142 
by each of high, medium, low or negligible Ki67 staining levels; (2) an unweighted global 143 
assessment; and (3) assessment of Ki67 only in a ‘hot-spot’ area.  144 
Global methods attempt to derive an average score across all the tissue available for 145 
assessment. In the weighted and unweighted global methods, Ki67 index counting was performed 146 
in the same fashion, but the final Ki67 score was derived differently. Adapted from a scoring 147 
protocol that has been used routinely in the Dowsett laboratory,31 these two global methods require 148 
the pathologist to first assess staining heterogeneity by estimating the percentages of the invasive 149 
tumour component of the slide exhibiting relatively high, medium, low or negligible Ki67 staining 150 
frequencies. Based on these estimates, an algorithm (Supporting information, Figure S2) dictates 151 
the required number of fields to select and score for each Ki67 staining frequency (irrespective of 152 
staining intensity, totalling up to four fields). This algorithm was designed such that the four (or 153 
fewer) selected scoring fields would capture the full range of staining frequencies, while at the 154 
same time be reflective of the proportion in staining frequencies heterogeneity. Up to 100 invasive 155 
tumour nuclei within each field are counted using a ‘typewriter’ pattern (Supporting information, 156 
Figure S3), similar to how a tissue microarray core was scored in the Phase II study.29  157 
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The hot-spot method requires the pathologist to visually select one high-power field with 158 
the highest apparent staining rate and, within that area only, count up to 500 invasive tumour nuclei 159 
in a ‘typewriter’ pattern. 160 
 161 
STATISTICAL ANALYSES 162 
Prespecified criterion for success 163 
Prior to data collection it was hypothesised that at least one of the scoring methods would have an 164 
associated ICC statistically greater than 0.80 (ICC of 0.8 being considered as good concordance32). 165 
For planning purposes, power calculations performed under a variety of scenarios considered to 166 
represent good reproducibility (and similar to the results observed in the Phase II study) showed 167 
that with at least 21 participating pathologists scoring 30 cases, there would be 80% power to 168 
exclude ICCs lower than the pre-specified ICC of 0.8 from a 95% credible interval for a given 169 
scoring method. 170 
 171 
Ki67 score 172 
The Ki67 score was defined as in the Phase IIIA study.30 Positive staining was defined as any 173 
brown stain in the nucleus above background, with reference available as needed to provide 174 
standard sample images; negative staining was scored when an invasive cancer cell showed only 175 
a blue counterstained nucleus. The unweighted global and hot-spot scores were simply the total 176 
number of positively stained tumour nuclei counted divided by the total number of tumour nuclei 177 
counted. The weighted global score was derived with tumour nuclei counts in each assessed field 178 
weighted by the estimated percentage of the total cancer area covered by each of high, medium, 179 
low or negligible Ki67 staining levels. As in our previous studies, to satisfy model assumptions of 180 
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normality and constant variance, for statistical analyses the Ki67 score is converted to a 181 
logarithmic scale by adding 0.1% and applying a log base 2 transformation.  182 
ICC estimates (ranging from 0 to 1, with 1 representing perfect reproducibility) were 183 
computed as previously reported in the Phase IIIA study.30 Briefly, variance component analyses 184 
were performed to quantify the contributions from the following sources of variability: scoring 185 
pathologist (observer), patient tumour (biological variation – each excision block represents a 186 
unique patient) and section of the excision block. Similar to the Phase IIIA study, same-section 187 
and different-section ICCs were computed. Same-section refers to pathologists scoring the same 188 
excision whole section physical slides, while different-section refers to pathologists scoring 189 
different physical slides that represent serial sections cut from the same original excision blocks. 190 
Credible intervals for the variance components and the ICCs were obtained using the Markov 191 
Chain Monte Carlo routines for fitting generalised linear mixed models. 192 
All data analyses were performed using R version 3.3.2.33 Sources of variation in log2-193 
transformed Ki67 scores were analysed using random effects models as implemented in the R 194 
packages lme4 and MCMCglmm. Data were visualised using heat maps, box-plots and spaghetti 195 
plots. 196 
 197 
Results 198 
ICC OF Ki67 ACCORDING TO SCORING METHOD 199 
The different-section ICC estimate for the weighted global scores was 0.87 (95% CI = 0.799–200 
0.93), at the margin of the prespecified success criterion (lower bound of credible interval 201 
exceeding 0.8) (Table 1). The different-section ICCs for the unweighted global scores and hot-202 
spot scores were 0.86 (95% CI = 0.793–0.92) and 0.83 (95% CI = 0.74–0.90), respectively, and 203 
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therefore both these methods had ICC credible intervals that extended below the success criterion 204 
at the lower 95% limit. The corresponding same-section ICC estimates for the weighted global, 205 
unweighted global and hot-spot scores were virtually identical 0.87 (95% CI = 0.799–0.92), 0.86 206 
(95% CI = 0.79–0.92) and 0.83 (95% CI = 0.74–0.90) respectively, supporting that differences 207 
between serial sections were minimal. Figure 1 displays the side-by-side box-plots of Ki67 scores 208 
among pathologists (hereafter referred to as ‘observers’) by group. Summary statistics for the Ki67 209 
scores among the 23 observers are given in Supporting information, Tables S2–S4. 210 
The median number of nuclei counted per slide (across all observers and cases) was 400 211 
and 500 for the global and hot-spot methods, respectively. The corresponding minimum number 212 
of nuclei counted was 300 and 138. Eighteen per cent of the hot-spot scores were based on < 500 213 
nuclei counts. Among these 126 hot-spot scores, the median number of nuclei counted was 375.  214 
In a context where pre-analytical and staining factors are held constant, variance 215 
component analyses show that, regardless of scoring method, biological variation among different 216 
patients was the largest component of the total variation on these centrally stained slides, indicating 217 
that the Ki67 score is reflecting inherent properties of the tumour (Figure 2, Supporting 218 
information, Table S5).  219 
 220 
INTEROBSERVER VARIATION OF KI67 SCORING 221 
Figure 3 displays the variation in scores across observers for cases in slide set 1 as spaghetti plots. 222 
The corresponding plots for slide sets 2–4 are displayed in Supporting information, Figure S4. 223 
Figure 4 presents the scores in a heat-map format with the columns (observers) ordered (within 224 
each slide set) by the median scores across cases and the rows (cases) sorted by the median scores 225 
across observers. 226 
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Overall, it can be seen that most observers show good parallelism in the increasing Ki67 227 
scores throughout the plots. In other words, observers measuring higher or lower than others 228 
tended to do so relatively consistently.  229 
 230 
CATEGORICAL CONCORDANCE OF KI67 SCORING 231 
Regarding concordance on a categorical level (< 10, 10–20 and > 20%), the relationship between 232 
concordance and continuous score is shown in Supporting information, Figure S5. It shows 233 
excellent to perfect concordance on cases with scores that are either much lower or higher than the 234 
intermediate range (10–20%).  235 
Based on visual inspection of captured images, locations of the hot-spot selections tended 236 
to cluster in the same region among observers within each of the excision whole-section slides 237 
(Figure 5 shows some examples; virtual slide images of all slides used in this study and the 238 
corresponding selected fields and scores can be viewed at 239 
http://www.gpec.ubc.ca/papers/ki67p3b).  240 
The median scoring time (field selection and nuclear counting) was 9 (interquartile range: 241 
7–11) and 6 (interquartile range = 4–8) minutes for global and hot-spot methods, respectively. 242 
 243 
Discussion 244 
The IKWG has demonstrated that it is possible, when controlling stringently for variability due to 245 
pre-analytical and analytical aspects of the Ki67 immunohistochemistry assay,9 and given a set of 246 
clearly defined training exercise and scoring instructions, for pathologists to achieve high 247 
interobserver concordance in Ki67 scoring on core-cut biopsies and now on excision whole 248 
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sections using a conventional light microscope and manual field selection, with no additional aid 249 
such as a counting grid.  250 
Due to the limited sample size, we were unable to assess whether any specific method 251 
(weighted global, unweighted global or hot-spot) is significantly more reproducible than others. 252 
However, the observed ICCs for global score (weighted = 0.87; unweighted = 0.86) are relatively 253 
higher compared to hot-spot score (0.83), suggesting that a sufficiently powered study might be 254 
able to show more convincingly whether global scores are more reproducible. This result is 255 
consistent with findings on core biopsies.30 256 
Can this level of concordance be clinically adequate? The POETIC11 study assessed Ki67 257 
(cut-point at 10%) as a prognostic marker. Applying this cut-point to the data in our current study, 258 
17 (of 30) cases have, at most, one discordance in weighted global score (Figure 4A). There are 259 
cases with major discrepancies: TB036, on the same physical slide (set 2), received a weighted 260 
global score of 4 and of 21% from observers A and L, respectively. However, it is apparent (Figure 261 
4) that cases far away from the intermediate range (10–20%) tend to have good agreement. 262 
Considering that cases in our current study are a random sampling of the general ER+ breast cancer 263 
population, one could expect that approximately half of these cases would fall away from the 264 
intermediate range, and hence Ki67 may provide clinically adequate information, provided that 265 
the staining and pre-analytical factors do not add too much variability.  266 
Are the proposed scoring methods practical? The median scoring time is 6–9 min, 267 
depending on the method used. However, an adaptive scoring protocol can be used to reduce 268 
scoring time if the purpose is to assess whether Ki67 is above or below a specific cut-point. For 269 
example, considering the global scoring method, where the maximum nuclei count is prespecified 270 
(i.e. 400), to determine whether a case has unweighted global score ≥ 10% the pathologist can stop 271 
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counting if the first field they scored is ≥ 40%. For cases with a very low Ki67 score, one would 272 
probably still need to count all 400 nuclei. 273 
The proposed scoring protocols do not make any recommendation concerning the required 274 
minimum tumour nuclei count. This is a limitation of this study and, in practice, it will be up to 275 
the discretion of the scoring pathologist to assess if too few tumour nuclei are available for an 276 
adequate Ki67 assessment. This will depend on the percentage of positive cells scored in the cells 277 
available and the clinical context for the measurement.  278 
An external quality assessment programme (e.g. NordiQC34), involving comparison of  279 
laboratory scores with reference scores in periodic assessment challenges, will probably improve 280 
interobserver reproducibility further. Recent studies suggest that an even higher level of 281 
concordance can be achieved with automated image analysis.35–38 The IKWG is actively 282 
conducting studies in this area to assess how artificial intelligence may help to standardise Ki67 283 
assessment.35,38 Also, concordance between Ki67 scores on core biopsies and excision specimens 284 
is currently being investigated.  285 
In conclusion, this study demonstrates that an adequately high level of interobserver 286 
concordance can be achieved by visual assessment of Ki67 using practical scoring methods, 287 
although some cases with large discrepancies remain. A two-tier assessment approach may be 288 
worthy of further study as a means to reduce scoring burden and further address challenging cases: 289 
if the Ki67 value from the initial scoring falls on a grey zone (e.g. cut-point ± 5%), scoring by a 290 
second pathologist or alternative test could be pursued. Pre-analytical and analytical aspects of the 291 
immunohistochemistry assay, areas that still need standardisation before the clinical utility of this 292 
marker can be proved, will probably add more variability. A clinical validation study employing 293 
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analytically reproducible methodology would also need to be completed in appropriate cohorts of 294 
cases to determine whether Ki67 can be recommended for patient care decisions.  295 
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  448 
Figure 1. Ki67 scores of all 23 observers (by slide set). Observers are ordered (within each group) 449 
by the median scores. The bottom/top of the box in each box plot represent the first (Q1)/third 450 
(Q3) quartiles, the bold line inside the box represents the median and the two bars outside the box 451 
represent the lowest/highest datum still within 1.5 × the interquartile range (Q3–Q1). Outliers are 452 
represented with empty circles. 453 
 454 
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21 
 
Figure 2. Variance component analysis. Variation due to different components are presented in a 455 
bar plot to show the relative magnitude of differences between them. Numerical values of the 456 
variance components estimates and the corresponding credible intervals are shown in Supporting 457 
information, Table S5. 458 
 459 
Figure 3. Variability in Ki67 scores (slide set 1 only). Each line represents Ki67 scores from one 460 
observer. Shaded region indicates Ki67 scores between 10 and 20%. Scores on slide sets 2–4 are 461 
shown in Supporting information, Figure S4. 462 
 463 
Figure 4. Heat-map of Ki67 scores (A, weighted global; B, unweighted global; C, hot-spot). Rows 464 
represent cases and columns represent observers. Green colour indicates that the score is < 10%, 465 
yellow 10–20% and red > 20%. Cases are ordered by the median scores (across observers), which 466 
are shown in parentheses beside the specimen number. Observers are ordered (within each group) 467 
by the median scores (across cases). The three colon-separated numbers to the right of the heat-468 
map represent the number of observers giving scores falling into different ranges: < 10% (left), 469 
10–20% (middle) and > 20% (right). For example, ‘15:6:1’ indicates that 15 observers gave a score 470 
of < 10%, six observers between 10 and 20% and one observer > 20%. 471 
 472 
Figure 5. Hot-spot field selection by different observers on the same excision whole section slide. 473 
A, Selections (indicated by red circles) on some example excision whole section slides. B, An 474 
example of a single excision whole section slide (median score: 18%) with zoomed-in fields. Each 475 
observer was asked to circle the area considered to be the hot-spot (B-i). Most observers honed in 476 
on the same general area of the slide, although individual selected scoring fields do not always 477 
22 
 
22 
 
overlap. B-iii and B-iv represent segments of the same area chosen by two different observers to 478 
read Ki67. Figure B-v represents the ‘outlier’ field selected by only one observer as the hot-spot.  479 
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c
Specimen Specimen
Specimen
a. Weighted global score
(median score) SLIDE SET 1 SLIDE SET 2 SLIDE SET 3 SLIDE SET 4
TB040 (0) 1 0 0 0 1 1 0 1 1 0 0 1 0 0 1 1 0 1 0 0 0 1 0 23:0:0
TB196 (3) 3 3 6 3 4 6 2 2 5 2 3 4 3 1 4 2 4 2 4 3 4 2 2 23:0:0
TB113 (6) 6 4 6 6 6 18 4 6 5 6 8 8 9 3 6 6 7 5 4 5 3 6 7 22:1:0
TB319 (6) 6 6 7 3 10 10 2 5 5 5 6 8 7 4 4 6 6 9 6 7 6 8 4 21:2:0
TB107 (6) 4 5 5 8 5 10 3 3 9 6 8 6 8 3 8 6 8 7 5 5 4 7 9 22:1:0
KMS13 (7) 7 5 8 3 8 9 2 2 8 4 11 12 9 4 10 17 11 4 8 7 3 4 6 18:5:0
TB016 (8) 6 8 8 8 10 15 5 7 8 9 11 13 21 8 13 10 10 10 6 8 7 12 7 13:9:1
KMS18 (9) 6 8 9 8 10 18 3 12 9 11 16 6 19 6 8 9 10 16 10 5 2 2 5 14:9:0
KMS3 (9) 7 9 14 9 16 12 7 7 9 7 9 8 12 9 16 12 15 12 6 11 9 11 9 13:10:0
TB022 (9) 7 8 10 5 10 15 3 10 6 13 15 5 5 8 10 7 9 7 10 6 11 11 14 12:11:0
KMS2 (10) 13 9 7 14 11 16 5 9 8 14 13 11 20 9 10 10 9 11 6 9 4 11 10 10:13:0
KMS8 (10) 11 10 12 9 18 22 9 10 10 18 15 8 22 10 11 17 10 14 8 7 9 9 10 7:14:2
KMS6 (12) 9 13 6 11 14 22 12 11 11 9 16 19 20 10 9 10 15 24 12 11 8 18 15 5:16:2
TB036 (12) 8 9 12 12 12 20 4 5 13 11 14 13 21 25 15 14 12 12 9 9 8 13 10 7:14:2
KMS11 (12) 16 10 12 13 10 23 12 14 10 11 14 10 22 7 14 19 16 7 10 12 11 11 14 2:19:2
KMS20 (14) 12 16 8 12 11 24 10 9 12 13 16 18 24 11 12 16 15 19 36 13 19 14 17 2:18:3
KMS21 (15) 11 13 16 14 16 15 11 6 11 21 30 19 24 10 15 15 20 22 11 10 15 13 17 1:18:4
TB090 (16) 14 15 17 14 15 24 20 16 11 17 15 11 16 11 21 10 22 21 14 14 20 20 22 0:18:5
KMS15 (17) 22 16 19 17 13 29 8 7 12 19 21 19 21 15 17 14 23 19 16 12 13 16 24 2:15:6
TB381 (18) 17 21 18 13 26 21 16 10 15 14 20 20 29 11 14 20 28 21 14 10 20 11 21 0:16:7
KMS14 (19) 25 27 17 19 20 24 10 12 15 15 14 28 28 16 24 15 26 20 15 24 19 18 25 0:14:9
TB083 (20) 21 18 26 23 21 32 25 10 19 19 24 19 29 15 23 17 18 20 9 16 24 28 17 1:11:11
KMS5 (25) 20 25 28 20 25 28 18 14 13 25 28 18 31 11 28 28 25 21 18 22 18 29 30 0:9:14
TB203 (26) 26 24 33 24 30 37 18 19 16 26 25 26 45 31 34 37 33 24 23 34 43 18 32 0:4:19
TB077 (30) 27 34 26 24 47 39 27 18 19 32 33 28 30 15 31 36 23 45 18 34 30 31 30 0:4:19
TB067 (32) 32 41 33 28 32 36 24 25 25 32 46 24 45 28 31 23 38 33 29 30 29 34 33 0:0:23
KMS23 (34) 35 28 35 30 47 49 24 25 32 30 38 35 46 34 39 43 45 34 30 34 34 34 40 0:0:23
TB250 (40) 40 47 46 34 39 47 42 32 37 39 44 41 51 40 50 46 50 35 27 32 40 31 40 0:0:23
KMS4 (42) 44 42 33 38 47 37 29 28 50 45 28 47 50 31 51 45 53 39 25 48 27 49 33 0:0:23
KMS19 (68) 81 75 68 67 83 64 88 60 74 70 68 62 64 61 68 81 77 82 62 58 61 62 67 0:0:23
B F E V G H A P R K T O L J I U M D Q W N X S
Sp
ec
im
en
Observer
(median score) SLIDE SET 1 SLIDE SET 2 SLIDE SET 3 SLIDE SET 4
TB040 (1) 0 2 0 1 1 1 0 1 1 1 2 0 2 0 2 1 0 1 2 1 0 2 0 23:0:0
TB196 (4) 6 3 3 4 6 5 2 2 5 5 4 2 2 4 4 2 4 2 3 4 4 5 4 23:0:0
TB319 (6) 7 6 3 8 8 10 2 4 5 9 7 5 8 4 4 6 7 8 6 6 5 8 4 22:1:0
TB113 (6) 4 6 6 7 6 9 4 7 5 8 8 6 8 4 6 6 7 5 5 4 3 6 8 23:0:0
TB107 (6) 6 5 8 6 6 11 3 3 10 6 8 8 8 2 8 6 10 7 5 5 4 7 10 19:4:0
TB016 (8) 8 5 8 10 9 15 6 7 8 13 11 8 21 7 13 10 10 9 8 6 6 12 8 14:8:1
KMS13 (8) 8 9 8 11 11 10 4 5 8 13 15 6 14 6 12 15 12 4 8 8 5 4 11 13:10:0
TB022 (10) 10 8 5 9 10 14 4 10 6 4 14 12 8 10 10 7 11 8 6 10 11 11 14 10:13:0
KMS2 (10) 9 18 13 12 7 16 5 10 8 11 13 15 21 10 10 9 10 12 10 6 5 11 11 7:15:1
KMS3 (10) 10 7 10 16 14 11 5 6 9 8 12 8 14 10 15 12 16 11 11 6 9 11 10 8:15:0
KMS6 (11) 11 10 11 14 6 21 14 9 10 19 17 10 18 11 9 10 16 21 10 12 7 17 18 4:17:2
TB036 (12) 9 8 12 12 12 19 4 5 12 13 14 10 23 29 15 14 12 12 9 9 8 13 12 7:14:2
KMS8 (12) 12 12 8 13 16 21 9 10 11 10 12 18 23 12 11 14 12 14 7 8 9 10 14 5:16:2
KMS11 (12) 14 15 14 13 19 24 12 11 12 10 13 12 27 11 12 20 13 8 12 12 10 11 15 1:20:2
KMS18 (14) 14 8 14 9 17 20 4 16 15 11 16 15 20 12 12 8 16 16 6 24 4 2 12 7:15:1
KMS21 (15) 15 10 14 15 16 14 11 6 11 18 26 19 27 12 14 15 19 21 11 13 15 13 20 1:19:3
KMS20 (15) 16 12 15 11 10 24 12 10 12 17 13 16 28 14 11 16 16 18 13 35 18 14 19 0:20:3
TB090 (18) 19 15 16 15 24 25 18 16 10 12 15 18 17 16 21 12 20 23 16 18 19 20 28 0:18:5
KMS15 (18) 13 22 18 18 21 26 8 10 19 19 25 18 22 16 16 14 22 19 15 16 16 17 26 1:15:7
TB381 (18) 21 26 15 25 18 22 19 10 17 15 23 18 32 14 13 18 30 22 12 16 20 16 22 0:14:9
KMS14 (20) 22 27 18 22 18 20 9 14 15 26 15 18 30 15 24 15 26 20 24 16 23 20 28 1:12:10
TB083 (21) 19 18 24 21 27 28 22 14 20 16 22 22 32 16 20 14 20 21 18 10 24 25 23 0:11:12
KMS5 (22) 26 20 21 25 28 28 15 14 13 16 24 22 31 11 27 28 24 18 22 20 18 29 29 0:9:14
TB077 (27) 30 26 20 44 27 31 19 22 19 28 34 24 32 18 27 36 22 28 32 24 30 28 23 0:4:19
TB203 (28) 20 29 28 30 37 36 23 20 20 24 27 24 40 27 34 33 33 25 34 24 34 22 31 0:3:20
TB067 (30) 38 30 26 32 32 28 24 22 25 25 33 30 42 26 30 24 36 30 30 31 30 34 29 0:0:23
KMS23 (34) 28 37 34 47 36 46 24 25 31 32 38 30 46 32 37 38 44 35 32 27 33 34 43 0:0:23
KMS4 (36) 31 42 37 47 35 31 32 27 50 40 33 34 44 28 48 38 56 36 49 28 24 51 36 0:0:23
TB250 (37) 25 34 36 38 44 40 42 31 36 39 36 34 48 37 50 46 45 36 30 22 38 33 37 0:0:23
KMS19 (66) 72 76 69 72 66 62 88 55 69 64 64 67 64 59 68 81 70 82 59 59 61 62 64 0:0:23
F B V G E H A P R O T K L J I U M D W Q N X S
b. Unweighted global score
Sp
ec
im
en
Observer
(median score) SLIDE SET 1 SLIDE SET 2 SLIDE SET 3 SLIDE SET 4
TB040 (1) 3 1 1 1 0 1 1 1 6 0 2 3 15 0 1 1 1 6 1 0 2 1 1 22:1:0
TB196 (6) 3 4 6 6 5 6 3 4 7 3 7 6 14 0 7 7 8 11 1 5 7 8 10 20:3:0
TB113 (8) 9 8 6 7 4 12 9 5 9 7 7 16 10 9 12 12 8 5 5 4 6 14 16 16:7:0
TB319 (9) 10 5 5 6 14 12 5 3 14 7 12 9 14 7 11 15 8 10 4 4 6 10 15 12:11:0
TB022 (10) 10 8 11 10 12 24 8 9 15 8 22 20 20 10 15 10 14 6 8 8 9 14 16 8:13:2
TB107 (12) 11 12 15 14 10 15 5 7 13 7 14 11 19 9 13 11 15 11 5 6 12 14 18 6:17:0
TB016 (14) 10 14 15 14 5 17 11 9 12 13 24 15 15 10 9 19 20 17 7 11 10 17 14 4:18:1
TB036 (14) 10 12 16 16 14 20 7 8 15 13 24 19 14 7 14 19 14 13 11 9 11 18 19 4:18:1
KMS3 (14) 11 23 20 25 26 24 8 12 5 16 29 24 14 9 20 12 20 14 4 9 9 11 22 6:10:7
KMS2 (16) 17 18 10 18 16 18 9 13 13 11 23 27 24 15 13 17 17 16 9 8 8 15 20 4:16:3
KMS13 (18) 12 15 23 19 13 25 12 18 21 18 31 26 31 18 16 6 24 21 2 14 13 17 15 2:13:8
KMS8 (18) 18 16 15 22 16 25 17 15 21 18 20 27 26 18 23 21 13 20 6 12 10 14 19 1:15:7
KMS20 (22) 19 22 20 20 22 38 17 20 20 23 35 27 29 22 22 27 25 29 21 17 22 23 28 0:7:16
KMS6 (22) 18 22 18 23 22 25 13 16 12 27 25 25 32 22 26 26 26 14 8 15 18 18 30 1:9:13
KMS5 (24) 25 24 28 29 30 27 23 15 14 23 33 35 37 28 21 24 22 34 24 17 20 23 33 0:4:19
KMS21 (24) 24 23 25 23 23 36 14 23 19 23 27 30 31 16 26 23 31 27 14 16 26 25 30 0:5:18
KMS11 (26) 22 23 28 28 28 34 14 12 29 17 35 33 39 29 21 26 25 26 15 21 30 25 33 0:4:19
KMS18 (28) 24 27 29 40 30 37 23 27 29 28 28 40 39 7 22 35 35 38 18 21 20 19 33 1:3:19
TB090 (30) 26 30 28 40 28 49 25 28 30 27 32 39 50 30 26 32 26 36 31 22 28 30 31 0:0:23
TB083 (31) 30 26 41 33 39 39 22 28 31 33 47 41 46 21 25 33 28 37 27 31 25 31 32 0:0:23
KMS15 (32) 32 32 34 31 34 37 13 26 30 27 25 39 39 30 26 32 32 27 27 18 32 37 37 0:2:21
KMS14 (34) 41 25 34 45 37 39 19 22 21 30 34 38 43 30 33 21 35 42 23 21 26 38 38 0:1:22
TB381 (35) 38 33 28 46 55 51 27 27 31 33 46 41 46 38 35 39 34 39 32 28 26 30 37 0:0:23
TB067 (43) 31 36 44 43 53 51 31 37 49 43 40 46 52 43 49 37 39 54 39 32 47 36 46 0:0:23
TB077 (45) 45 44 46 44 64 56 25 36 43 31 50 50 49 44 52 46 34 41 43 33 52 49 48 0:0:23
TB203 (47) 37 40 58 50 50 54 39 42 42 41 47 50 50 45 48 40 48 51 44 47 48 46 52 0:0:23
KMS23 (48) 52 41 46 53 58 55 42 34 42 36 52 48 55 55 52 41 51 47 46 43 43 48 57 0:0:23
TB250 (53) 48 44 57 62 57 64 32 43 48 47 51 60 54 56 54 69 53 57 40 48 49 53 49 0:0:23
KMS4 (56) 56 48 58 70 68 64 38 51 64 45 58 68 54 48 53 53 51 63 55 39 57 61 63 0:0:23
KMS19 (76) 81 83 78 97 94 76 92 68 66 65 64 79 74 71 81 82 67 84 64 66 81 56 70 0:0:23
B V E F G H A P R O L K T U M D J I Q N W X S
c. Hot-spot score
Sp
ec
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en
Observer
a
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b-i
D:5.6%
b-v
M:16.2%
b-iii
J:23.6%
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